Summary & Overview
HCPCS G9206: Hepatitis C Antiviral Treatment Initiation
HCPCS Level II code G9206 indicates that a patient began antiviral treatment for hepatitis C during the measurement period. As a measure-capture code, it documents treatment initiation and supports quality reporting, care coordination, and population health monitoring for hepatitis C management across outpatient and ambulatory care settings. Nationally, accurate use of this code helps track progress toward treatment access and outcomes for hepatitis C, a priority public health goal.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of the code’s clinical intent and reporting context, benchmarks and coverage patterns where available, and relevant policy considerations affecting measurement and reimbursement. The publication summarizes how G9206 is used in practice to mark the start of antiviral therapy, the typical sites of service for initiation, and what elements are commonly included in related reporting workflows.
This resource is intended for health policy analysts, billing and coding professionals, quality improvement leaders, and clinical managers seeking a concise national perspective on the role of HCPCS Level II code G9206 in hepatitis C treatment tracking and related reporting activities.
Billing Code Overview
HCPCS Level II code G9206 denotes a patient who is starting antiviral treatment for hepatitis C during the measurement period. This code captures initiation of antiviral therapy as an event for quality measurement and reporting.
-
Service type: Antiviral treatment initiation for hepatitis C
-
Typical site of service: Outpatient clinic or ambulatory care setting where hepatitis C treatment is prescribed or started
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient scenario involves an adult with chronic hepatitis C virus (HCV) infection who presents to an outpatient hepatology or infectious disease clinic during the measurement period and is newly prescribed direct-acting antiviral (DAA) therapy. The patient has confirmatory HCV RNA testing and genotype assessment completed prior to prescription. During the visit the clinician documents treatment initiation, counsels the patient on adherence and potential side effects, verifies baseline liver function and renal function laboratory results are available, and arranges medication access through the patient’s pharmacy and payer prior authorization if required. The clinical workflow includes: scheduling the intake visit; reviewing prior labs (HCV RNA, genotype, liver fibrosis staging such as transient elastography or FIB-4); obtaining baseline labs (CBC, CMP, creatinine, hepatic panel, pregnancy test if applicable); counseling and consent for DAA therapy; documenting start date in the medical record; completing any payer prior authorization; coordinating medication delivery; and arranging follow-up for on-treatment monitoring and sustained virologic response testing at 12 weeks post-treatment (SVR12). Typical sites of service are outpatient clinic visits, specialty hepatology or infectious disease clinics, and community health centers. Typical service type is outpatient medication initiation and care coordination for antiviral therapy.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 | Significant, separately identifiable evaluation and management service by the same physician on the same day of the procedure or other service |